{
    "clinical_study": {
        "@rank": "77370", 
        "arm_group": {
            "arm_group_label": "TAK-816 0.5 mL", 
            "arm_group_type": "Experimental", 
            "description": "Primary immunization:\nThree 0.5-mL doses of the vaccine will be intramuscularly injected at intervals of 28 days. In principle, the vaccine will be injected into the anterolateral aspect of the thigh, alternating between left and right.\nBooster immunization:\nOne 0.5-mL booster dose of the vaccine will be intramuscularly injected into the anterolateral aspect of the thigh at 52 weeks after the third dose."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety of intramuscular TAK-816 in healthy\n      Japanese infants."
        }, 
        "brief_title": "Phase III Study of Intramuscular TAK-816 in Healthy Infants", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prevention of Infections Caused by Haemophilus Influenzae Type b", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to evaluate the safety of intramuscular TAK-816 in healthy\n      Japanese infants. The secondary purpose of this study is to evaluate the immunogenicity of\n      intramuscular TAK-816 in healthy Japanese infants."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy Japanese infants\n\n          2. Male or female infants aged 2-6 months (\u22652 and <7 months) at the time of the first\n             dose of investigational product (excluding hospitalized infants)\n\n          3. Infants whose parents or legal guardians have agreed to cooperate with the\n             investigator during the study period.\n\n        Exclusion Criteria:\n\n          1. Any serious acute illness.\n\n          2. Any underlying cardiovascular, renal, hepatic, or hematologic disease, and/or\n             developmental disorder.\n\n          3. History of possible Haemophilus influenzae type b (Hib) infection.\n\n          4. Previously diagnosed immunodeficiency.\n\n          5. Documented history of anaphylaxis to any ingredients of the investigational product\n             (e.g., diphtheria toxoid)\n\n          6. A history of convulsions.\n\n          7. Previous administration of another Hib vaccine.\n\n          8. Treatment with any live vaccine during the 27 days before the first dose of TAK-816\n             or with any inactivated vaccine during the 6 days before dosing.\n\n          9. Prior participation in any clinical study or post-marketing clinical study\n\n         10. Previously receipt of blood transfusions, gamma globulin preparations (except\n             monoclonal vaccines as antigens), systemic immunosuppressive therapy, or systemic\n             corticosteroids, or a plan to receive any of these products during the study period\n\n         11. Presence of thrombocytopenia or coagulopathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "6 Months", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074345", 
            "org_study_id": "TAK-816/OCT-002", 
            "secondary_id": "U1111-1153-4027"
        }, 
        "intervention": {
            "arm_group_label": "TAK-816 0.5 mL", 
            "description": "TAK-816 injection", 
            "intervention_name": "TAK-816 0.5 mL", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kumagaya-shi", 
                        "country": "Japan", 
                        "state": "Saitama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fuchu-shi", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suginami-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koufu-shi", 
                        "country": "Japan", 
                        "state": "Yamanashi"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase III, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of Intramuscular TAK-816 in Healthy Infants", 
        "overall_contact": {
            "email": "medicalinformation@tpna.com", 
            "last_name": "Takeda Study Registration Call Center", 
            "phone": "+1-800-778-2860 (USA & EU)"
        }, 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Senior Manager", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The frequencies of all adverse reactions observed during the observation period will be tabulated by type and seriousness. Adverse events are defined as unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product, regardless of relationship to the medicinal product. Among these, events which are considered possibly associated with a medicinal product are defined as adverse reactions.", 
                "measure": "Frequency of Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "For 64 weeks"
            }, 
            {
                "description": "For body temperature, summary statistics of baseline values and observed values at each time point of evaluation will be calculated.", 
                "measure": "Body temperature", 
                "safety_issue": "Yes", 
                "time_frame": "For 64 weeks"
            }, 
            {
                "description": "On the basis of health diary entries which subject's caregiver records, local and systemic reactions will be summarized using frequency distributions.", 
                "measure": "Health diaries", 
                "safety_issue": "Yes", 
                "time_frame": "For 64 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074345"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "At each time point of evaluation, the proportion of subjects with an anti-PRP antibody titer \u2265 1.0 \u03bcg/mL (i.e., antibody response rate with a threshold of 1.0 \u03bcg/mL) and the proportion of subjects with an anti-PRP antibody titer \u2265 0.15 \u03bcg/mL (i.e., antibody response rate with a threshold of 0.15 \u03bcg/mL) will be summarized using frequency distributions, and a calculation of point estimates and two-sided 95% confidence intervals will be performed. For anti-PRP antibody titers, summary statistics, geometric mean titer (GMT), and two-sided 95% confidence intervals for the GMT will be calculated.", 
                "measure": "Proportion of subjects with anti-polyribosylribitol phosphate (PRP) antibody response", 
                "safety_issue": "No", 
                "time_frame": "For 64 weeks"
            }, 
            {
                "description": "To calculate the two-sided 95% confidence interval for the GMT at each time point of evaluation, the mean of log-transformed antibody titer values will be calculated first, and then the upper and lower limits of the two-sided 95% confidence interval for the mean will be inverse log-transformed.", 
                "measure": "Geometric mean titer (GMT) of anti-PRP antibody", 
                "safety_issue": "No", 
                "time_frame": "For 64 weeks"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}